KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Entries in KLH-MUC (10)

Thursday
Mar052009

NCT00857545

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase II

Friday
Jun132008

NCT00698711

Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I

Monday
May132002

NCT00036933

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center 
Phase II

Thursday
Feb142002

NCT00030823

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

Conditions: Breast Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I

Sunday
May062001

NCT00016120

Vaccine Therapy Plus Biological Therapy in Treating Patients With Relapsed Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase II

Sunday
May062001

NCT00016146

Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I 

Wednesday
Jul052000

NCT00006041

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I

Tuesday
May022000

NCT00005632

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I

Tuesday
Mar072000

NCT00004929

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase II

Friday
Dec101999

NCT00004156

Vaccine Therapy in Treating Patients With Breast Cancer

Conditions: Breast Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase II